Thyrocare Technologies Ltd

Thyrocare Technologies Dividend

Thyrocare Technologies recommended a final dividend of Rs. 7.00 per share for FY2025-26. Total annual dividend reached Rs. 9.33 per share following shareholder approval.

Thyrocare Technologies Results Update

Thyrocare Technologies reported FY26 consolidated revenue of ₹829.04 Crore, up 21% YoY. Net profit surged 81% to ₹162.85 Crore, driven by pathology segment growth.

Value

₹829.0 Cr

Thyrocare Technologies Earnings Call: Key Takeaways

Thyrocare reports strong performance for Q4FY26 and FY26 with significant YoY growth in PAT and EBITDA driven by network expansion and operational efficiencies.

Thyrocare Technologies Earnings Call: Key Takeaways

Thyrocare reports robust growth for Q4FY26 and FY26, driven by franchise expansion and new specialty launches like Genomics and Allergy testing.

Thyrocare Technologies Q4 FY26 Results: Net Profit ₹48.7 Cr, Up 125.5% YoY

Thyrocare Technologies Ltd reported revenue from operations of ₹223.9 Cr (+19.6% YoY) and net profit of ₹48.7 Cr (+125.5% YoY) for Q4 FY26.

Key figure

Net profit ₹48.7 Cr · +125.5% YoY

Thyrocare Technologies Financial Results

Thyrocare Technologies reported FY26 consolidated revenue of ₹829.04 Crore and PAT of ₹162.85 Crore. The Board recommended a final dividend of ₹7.00 per share and approved the appointment of Price Waterhouse LLP as Statutory Auditors. The company also announced a ₹5.50 Crore investment in its wholly-owned subsidiary, Think Health Diagnostics.

Thyrocare Technologies Other Announcement

Thyrocare Technologies Ltd has cancelled its Earnings Conference Call originally scheduled for May 07, 2026, at 5:30 P.M. (IST) due to unforeseen circumstances. The call was intended to discuss the company's audited financial results for the quarter and year ended March 31, 2026. A revised schedule will be announced later.

Thyrocare Technologies Board Meeting Date

Thyrocare Technologies Limited has scheduled a Board Meeting for May 7, 2026. The board will consider audited standalone and consolidated financial results for the year ended March 31, 2026, and recommend a final dividend. The trading window remains closed until May 9, 2026.

Thyrocare Technologies Board Meeting Date

Thyrocare Technologies Ltd will hold a Board meeting on May 07, 2026, to approve audited financial results for FY26 and recommend a final dividend. The company's trading window closed on April 01, 2026, and will reopen 48 hours after the results declaration.

Thyrocare Technologies Q3 FY26 Results: Net Profit ₹28.1 Cr, Up 48.7% YoY

Thyrocare Technologies Ltd reported net profit of ₹28.1 Cr (+48.7% YoY) for Q3 FY26.

Key figure

Net profit ₹28.1 Cr · +48.7% YoY

Thyrocare Technologies Other Announcement

Thyrocare Technologies submitted its Regulation 74(5) compliance certificate for the quarter ended March 31, 2026. The Registrar and Share Transfer Agent confirmed that the entire shareholding is in dematerialised form and no rematerialisation requests were received during the period.